Cambridge, Mass.-based Genzyme Corp. submitted marketing applications in the U.S and Europe for its lymphoma and multiple myeloma treatment Mozobil (plerixafor), a small-molecule CXCR4 chemokine receptor antagonist. (BioWorld Today)